Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Morton Coleman

Showing results (81-90 of 118) with videos related to

Pageof 12
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 11, 2008
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myelomaTomer Mark, Jessica Stern, Jessica R Furst, et al.
Leukemia & Lymphoma|March 1, 2014
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myelomaTomer M Mark, Isaac A Bowman, Adriana C Rossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2009
Outcome of deferred initial therapy in mantle-cell lymphomaPeter Martin, Amy Chadburn, Paul Christos, et al.
Blood Advances|March 31, 2021
Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patientsJoachim Yahalom, Amy J Xu, Ariela Noy, et al.
British Journal of Haematology|August 10, 2007
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapyRuben Niesvizky, Tara Naib, Paul J Christos, et al.
The New England Journal of Medicine|May 30, 2014
Ibrutinib resistance in chronic lymphocytic leukemiaRichard R Furman, Shuhua Cheng, Pin Lu, et al.
Blood|September 6, 2018
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphomaJia Ruan, Peter Martin, Paul Christos, et al.
Haematologica|March 18, 2021
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemiaKerry A Rogers, Philip A Thompson, John N Allan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphomaJohn P Leonard, Morton Coleman, Jamie Ketas, et al.
American Journal of Hematology|August 23, 2021
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myelomaPeter A Forsberg, Adriana C Rossi, Angelique Boyer, et al.
Pageof 12

Showing results (81-90 of 118) with videos related to

Sort By:
Pageof 12
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 11, 2008
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myelomaTomer Mark, Jessica Stern, Jessica R Furst, et al.
Leukemia & Lymphoma|March 1, 2014
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myelomaTomer M Mark, Isaac A Bowman, Adriana C Rossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2009
Outcome of deferred initial therapy in mantle-cell lymphomaPeter Martin, Amy Chadburn, Paul Christos, et al.
Blood Advances|March 31, 2021
Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patientsJoachim Yahalom, Amy J Xu, Ariela Noy, et al.
British Journal of Haematology|August 10, 2007
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapyRuben Niesvizky, Tara Naib, Paul J Christos, et al.
The New England Journal of Medicine|May 30, 2014
Ibrutinib resistance in chronic lymphocytic leukemiaRichard R Furman, Shuhua Cheng, Pin Lu, et al.
Blood|September 6, 2018
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphomaJia Ruan, Peter Martin, Paul Christos, et al.
Haematologica|March 18, 2021
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemiaKerry A Rogers, Philip A Thompson, John N Allan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphomaJohn P Leonard, Morton Coleman, Jamie Ketas, et al.
American Journal of Hematology|August 23, 2021
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myelomaPeter A Forsberg, Adriana C Rossi, Angelique Boyer, et al.
Pageof 12